Jazz Pharmaceuticals plc — Director's Dealing 2016

Apr 15, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2016-04-13

Reporting Person: Smith Karen L. (Global Head of R&D and CMO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-04-13	Ordinary Shares	F	103.0	$147.34	Disposed	13040	Direct

Footnotes

F1: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units.